News articles about Pfizer (NYSE:PFE) have trended positive on Monday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 6,000 news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pfizer earned a news sentiment score of 2.19 on their scale. InfoTrie also gave press coverage about the biopharmaceutical company an news buzz score of 7 out of 10, indicating that recent press coverage is likely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Pfizer’s ranking:
- Pfizer (PFE) Receives Daily News Sentiment Score of 2.19 (americanbankingnews.com)
- Pfizer Inc. (PFE) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- Global Overactive Bladder Treatment Drug Market Insights 2018-2025: Astellas Pharma, Inc. , Pfizer, Inc. – Market Analysis News (marketanalysisnews.com)
- Staggering Facts About Pfizer Inc. (PFE) – KYMA News (kymanews.com)
- Shocking corollary – Pfizer Inc., (NYSE: PFE) – Nyse NewsToday (nysenewstoday.com)
Pfizer stock opened at $46.23 on Monday. The firm has a market capitalization of $275.20 billion, a P/E ratio of 17.45, a price-to-earnings-growth ratio of 2.30 and a beta of 0.88. Pfizer has a 52 week low of $33.20 and a 52 week high of $46.26. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 2.94%. Pfizer’s payout ratio is currently 51.32%.
A number of equities analysts have recently weighed in on the company. Atlantic Securities reissued a “buy” rating and issued a $54.00 price target on shares of Pfizer in a report on Tuesday, November 27th. Credit Suisse Group set a $42.00 price target on Pfizer and gave the stock a “hold” rating in a report on Monday, November 26th. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Monday, November 19th. Citigroup boosted their price target on Pfizer from $34.00 to $37.00 and gave the stock a “sell” rating in a report on Tuesday, November 6th. Finally, BMO Capital Markets cut Pfizer from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $47.00 to $46.00 in a report on Thursday, November 1st. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $43.27.
In other Pfizer news, major shareholder Pfizer Inc bought 55,556 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2018/12/03/pfizer-pfe-given-media-sentiment-score-of-2-19.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: How Investors Use a Balance Sheet
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.